

Vaccines for Children (VFC) Program Meningococcal ACWY Conjugate Vaccine Summary July 13, 2021

Purpose of vaccine summary

Effective July 13, 2021 MenQuadfi (MenACWY) vaccine, manufactured by Sanofi Pasteur, is available to order through the Iowa VFC Program. In addition to Menveo and Menactra, MenQuadfi may be used for active immunization against meningococcal A, C, W, Y disease.

Meningococcal (ACWY) Vaccination Food and Drug Administration (FDA)

MenQuadfi (MenACWY-TT) manufactured by Sanofi Pasteur
Approved for use in ages 2 years and older

Menactra (MCV4-D) manufactured by Sanofi Pasteur
Approved for use in ages 9 months-55 years

Menveo (MCV4-CRM) manufactured by GlaxoSmithKline
Approved for use in ages 2 months-55 years

Advisory Committee on Immunization Practices (ACIP)

[Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020](#)

VFC Resolution - the VFC Program follows the ACIP recommendations for the use of meningococcal conjugate vaccines for VFC eligible children through 18 years of age.

Indications and Usage:

Meningococcal conjugate vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y and, W-135. Although each of the three MenACWY vaccine products use a different protein conjugate, the products are considered interchangeable; the same vaccine product is recommended, but not required, for all doses. Meningococcal A, C, W, Y vaccines do not provide protection against serogroup B disease.

ACIP recommendations for the use of quadrivalent meningococcal conjugate vaccine (MenACWY):

- Routine vaccination for adolescents aged 11 or 12 years, with a booster dose at age 16. Persons who receive their first dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose.
- Routine vaccination of persons aged ≥ 2 months at increased risk for meningococcal disease (dosing schedule varies by age and indication, and interval for booster dose varies by age at time of previous vaccination):

- Persons with certain medical conditions including anatomic or functional asplenia, complement component deficiencies (e.g., C3, C5-C9, properdin, factor H, or factor D), complement inhibitor (e.g., eculizumab [Soliris] or ravulizumab [Ultomiris]) use, or human immunodeficiency virus infection.
- Microbiologists with routine exposure to *Neisseria meningitidis* isolates.
- Persons at increased risk during an outbreak (e.g., in community or organizational settings, and among men who have sex with men [MSM]).
- Persons who travel to or live in countries in which meningococcal disease is hyperendemic or epidemic.
- Unvaccinated or undervaccinated first-year college students living in residence halls.
- Military recruits.
- Booster doses for previously vaccinated persons who become or remain at increased risk. Detailed recommendations are available [here](#).

Recommended Dosage and Administration:

The recommended dose for each of the MenACWY vaccines is 0.5mL administered by intramuscular route. The Menveo product requires reconstitution. Refer to package inserts for detailed manufacturer guidance.

Vaccine Storage and Handling

- Store refrigerated at 2 - 8° C (35 - 46° F).
- Do not freeze. Protect from light.
- Do not use if product is exposed to out of range temperatures.
- Do not use after the expiration date.

Precautions:

- Moderate or severe acute illness with or without fever.
- Because vaccinees may develop syncope, sometimes resulting in falling with injury, observation for 15 minutes after vaccination is recommended.

Contraindications:

Severe allergic reaction (e.g. anaphylaxis) after a previous dose or to a vaccine component.

School Requirements

Meningococcal conjugate vaccine (MenACWY) is required for school enrollment under Iowa Code, Chapter 139a.8(6) and Iowa Administrative Code, 641-7.7(139). Detailed information on Iowa's immunization requirements is available [here](#).

IDPH/Immunization Program Recommendations

IDPH Immunization Program routinely follows and promotes the Recommended Immunization Schedule. The Immunization Program is implementing the addition of MenQuadfi vaccine as an option for MenACWY vaccination in accordance with ACIP recommendations and the federal VFC resolution.

CPT Code Meningitis Conjugate Vaccine code: 90619